These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 24371842)
1. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Coeytaux RR; Schmit KM; Kraft BD; Kosinski AS; Mingo AM; Vann LM; Gilstrap DL; Hargett CW; Heidenfelder B; Dolor RJ; McCrory DC Chest; 2014 May; 145(5):1055-1063. PubMed ID: 24371842 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials. Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870 [TBL] [Abstract][Full Text] [Related]
3. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis. Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518 [TBL] [Abstract][Full Text] [Related]
5. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis. Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD. He CJ; Chen SJ; Wang J; Zhu CY; Yin YH Pulm Pharmacol Ther; 2015 Jun; 32():24-8. PubMed ID: 25843006 [TBL] [Abstract][Full Text] [Related]
7. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. Johnson SR; Brode SK; Mielniczuk LM; Granton JT Respir Med; 2012 May; 106(5):730-9. PubMed ID: 22366298 [TBL] [Abstract][Full Text] [Related]
9. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis. Zhu B; Wang L; Sun L; Cao R J Cardiovasc Pharmacol; 2012 Oct; 60(4):342-6. PubMed ID: 22691882 [TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Ryerson CJ; Nayar S; Swiston JR; Sin DD Respir Res; 2010 Jan; 11(1):12. PubMed ID: 20113497 [TBL] [Abstract][Full Text] [Related]
11. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ; Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Bai Y; Sun L; Hu S; Wei Y Cardiology; 2011; 120(3):157-65. PubMed ID: 22212696 [TBL] [Abstract][Full Text] [Related]
13. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension. Petrovič M; Locatelli I Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058 [No Abstract] [Full Text] [Related]
15. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. Vizza CD; Jansa P; Teal S; Dombi T; Zhou D BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133 [TBL] [Abstract][Full Text] [Related]
16. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials. Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912 [TBL] [Abstract][Full Text] [Related]
17. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443 [TBL] [Abstract][Full Text] [Related]
18. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy. Small M; Piercy J; Pike J; Cerulli A Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285 [TBL] [Abstract][Full Text] [Related]
19. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis. Zhang HD; Zhang R; Jiang X; Sun K; Wu DC; Jing ZC Am Heart J; 2015 Jul; 170(1):96-103, 103.e1-14. PubMed ID: 26093869 [TBL] [Abstract][Full Text] [Related]